Compare Vanguard S&P 500 ETF (VOO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard S&P 500 ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard S&P 500 ETF trades at $715.59 (market cap $1.80T), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Vanguard S&P 500 ETF is far larger — about 178× State Street SPDR S&P Biotech ETF's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard S&P 500 ETF for 55 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| VOO | XBI | |
|---|---|---|
Market Cap | $1.80T | $10.11B |
Volume | 4,722,271 | 12,903,266 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $716.17 | $169.55 |
52-Week Low | $580.93 | $104.99 |
Typical Hold Time | 55 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VOO trades at $711.37, down 0.43% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF maintains strong institutional support despite a 46.9% increase in short interest reported by Defense World on October 3, 2026. Recent news highlights VOO's role as a core holding for long-term wealth building, with dividend payments scheduled for September 30, 2026.
VOO offers diversified exposure to S&P 500 companies with strong earnings growth projections of 35% for 2026. While short-term volatility may persist amid Federal Reserve policy uncertainty, the ETF remains well-positioned for investors seeking broad market participation. Key risks include potential earnings growth deceleration to 15% in 2027 and broader market valuation concerns.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
